ILC is the second most common type of invasive breast cancer, accounting for about 10–15% of cases. It originates from the lobules (milk-producing glands) and is characterized by small, uniform cancer cells invading the breast stroma in a single-file pattern due to loss of E-cadherin expression. Key Points:
- Hormone Receptor Status: Usually strongly ER-positive and PR-positive, HER2-negative in most cases.
- Clinical Features: Often presents as a palpable mass or breast thickening; can be multifocal and bilateral.
- Diagnosis: Imaging (mammogram, MRI) can be challenging; often requires biopsy for confirmation.
- Prognosis: Slightly better or comparable to invasive ductal carcinoma but with higher likelihood of multifocality and bilaterality.
- Treatment: Similar to invasive ductal carcinoma — surgery, radiation, chemotherapy, and endocrine therapy based on receptor status.
- Pharmacist Role:
- Counsel on endocrine therapy adherence (e.g., tamoxifen, aromatase inhibitors).
- Monitor and manage side effects (e.g., hot flashes, bone health).
- Support patients through complex regimens and coordinate care.
Treatment
Surgery:
- Typically lumpectomy or mastectomy, often followed by radiation.
- Due to multifocal/bilateral nature, surgical planning can be complex.
- Usually recommended after breast-conserving surgery to reduce local recurrence.
- Pharmacist can assist in managing radiation-related side effects (skin reactions, fatigue).
Systemic Therapy:
- Endocrine Therapy (Mainstay in ER+/PR+ ILC):
- Premenopausal patients:
- Tamoxifen 20 mg daily for 5–10 years.
- Ovarian suppression (e.g., GnRH agonists like goserelin) may be added in high-risk cases.
- Postmenopausal patients:
- Aromatase inhibitors (anastrozole 1 mg daily, letrozole, exemestane) preferred due to improved efficacy.
- Pharmacist role:
- Premenopausal patients:
- Chemotherapy:
- Indicated based on tumor size, nodal involvement, grade, and genomic assays (e.g., Oncotype DX).
- Common regimens similar to invasive ductal carcinoma:
- Anthracycline + cyclophosphamide followed by taxane (AC-T) or
- TC regimen (docetaxel + cyclophosphamide).
- Pharmacist responsibilities include dosing verification, toxicity monitoring (myelosuppression, nausea, neuropathy), and supportive care.
- Targeted Therapy:
- Bone-Directed Therapy:
- For patients with bone metastases, bisphosphonates or denosumab may be used to reduce skeletal events.
- Pharmacist should monitor for hypocalcemia and osteonecrosis of the jaw.
Summary for Oncology Pharmacists:
| Treatment Component | Key Points & Pharmacist Role |
|---|---|
| Endocrine therapy | Counsel on side effects, adherence; monitor bone health |
| Chemotherapy | Support toxicity management; verify dosing |
| Surgery & Radiation | Support side effect management |
| Targeted therapy (if HER2+) | Monitor cardiac function and infusion reactions |
| Bone-directed therapy | Monitor calcium levels; counsel on dental hygiene |
Pharmacotherapy Considerations in Invasive Lobular Carcinoma (ILC)
| Therapy Type | Agents & Dosing | Pharmacist Considerations | Common Side Effects & Management | Monitoring Parameters |
|---|---|---|---|---|
| Endocrine Therapy | ||||
| • Tamoxifen | 20 mg PO daily for 5–10 years | – Counsel on adherence and long-term use | Hot flashes, increased VTE risk, endometrial changes | Monitor for VTE symptoms, gynecologic bleeding; CYP2D6 drug interactions (e.g., SSRIs) |
| • Aromatase Inhibitors (AIs) | Anastrozole 1 mg PO daily; Letrozole, Exemestane | – Prefer in postmenopausal women | Arthralgia, osteoporosis, hot flashes | Bone density scans (DEXA), calcium/vitamin D supplementation, manage joint symptoms |
| • Ovarian Suppression | Goserelin 3.6 mg SC monthly (if premenopausal) | – Used with tamoxifen or AI in high-risk premenopausal pts | Menopausal symptoms, bone loss | Monitor bone health, menopausal symptom management |
| Chemotherapy | ||||
| • Anthracycline + Cyclophosphamide (AC) | Doxorubicin 60 mg/m² + Cyclophosphamide 600 mg/m² IV q3w ×4 cycles | – Monitor cumulative anthracycline dose (cardiotoxicity) | Myelosuppression, nausea, alopecia, cardiotoxicity | CBC before each cycle, echocardiogram, liver/renal function tests |
| • Taxanes | Paclitaxel 80 mg/m² weekly ×12 or Docetaxel 75 mg/m² q3w ×4 | – Premedicate for hypersensitivity; neuropathy monitoring | Peripheral neuropathy, myelosuppression | Neurologic assessment, CBC, infusion reactions |
| • Dose-Dense Regimens | AC followed by paclitaxel every 2 weeks with growth factor support | – Ensure G-CSF support for neutropenia | Similar to above with added risk of febrile neutropenia | CBC, patient education on infection signs |
| Targeted Therapy | ||||
| • Trastuzumab (if HER2+) | 8 mg/kg IV loading dose, then 6 mg/kg q3w | – Monitor cardiac function closely due to cardiotoxicity | Infusion reactions, cardiotoxicity | Baseline and periodic LVEF, infusion reaction monitoring |
| Bone-Directed Therapy | ||||
| • Bisphosphonates | Zoledronic acid 4 mg IV q3–4 weeks | – Prevent/treat AI-induced osteoporosis | Flu-like symptoms, rare osteonecrosis of jaw | Dental exams prior to treatment, serum calcium monitoring |
| • Denosumab | 120 mg SC q4 weeks | – Alternative for patients with renal impairment | Hypocalcemia, osteonecrosis of jaw | Calcium/vitamin D supplementation, serum calcium |
Additional Pharmacist Roles in ILC Management:
- Adherence Counseling: Long duration of endocrine therapy requires strong patient education and support.
- Side Effect Management: Early identification and management of menopausal symptoms, arthralgia, neuropathy, and cardiotoxicity.
- Drug Interaction Checks: Especially tamoxifen with CYP2D6 inhibitors (e.g., some antidepressants).
- Supportive Care Coordination: For chemotherapy-induced nausea, growth factor support, bone health.
- Monitoring & Labs: CBC, liver/renal function, cardiac imaging, bone density scans at appropriate intervals.
- Patient Education: Inform about therapy goals, potential side effects, and when to report symptoms urgently (e.g., signs of VTE, cardiac symptoms).